Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On

Cablevisión Holding S.A. (CVHSY) Q3 2026 Earnings Call Prepared Remarks Transcript

16 November 2026

Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript

16 November 2026

TOYO Co., Ltd. (TOYO) Q3 2026 Earnings Call Transcript

16 November 2026

Creative Realities, Inc. (CREX) Q3 2026 Earnings Call Transcript

16 November 2026

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

16 November 2026
Facebook X (Twitter) Instagram
Business Monday, Nov 16
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript
News

Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript

thebusinesstimes.co.ukBy thebusinesstimes.co.uk16 November 20261 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Share
Facebook Twitter LinkedIn Pinterest Email

Raphi Levy
Chief Financial Officer

Good morning. Thank you, everybody, for joining us this morning to talk about the newest Alpha DaRT results coming out of our REGAIN study for recurrent glioblastoma. We are thrilled to be here this morning together to discuss the results that were just presented at the Annual Meeting of the Society of Neuro-Oncology in Philadelphia over the weekend.

Today, I’m joined by Uzi Sofer, our CEO; Dr. Robert Den, our Chief Medical Officer; and Dr. Joshua Palmer, who is a Professor of Radiation Oncology at The James at Ohio State University as well as principal investigator of the REGAIN study. Today, what we’re going to do is we’re going to review the mechanism of the Alpha DaRT in a quick refresher. We’ll move into the results that were discussed and released over the weekend, the interim results from the REGAIN trial. We’ll look at a patient-by-patient overview and then leave time at the end for a summary and for questions and answers.

So with that, I’ll turn it over to my colleague, Dr. Den, to do a quick refresh of the Alpha DaRT mechanism.

Robert Den
Chief Medical Officer & Member of Scientific Advisory Board

Thank you, Raphi, very much. It’s a pleasure to be with all of you

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Cablevisión Holding S.A. (CVHSY) Q3 2026 Earnings Call Prepared Remarks Transcript

TOYO Co., Ltd. (TOYO) Q3 2026 Earnings Call Transcript

Creative Realities, Inc. (CREX) Q3 2026 Earnings Call Transcript

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

Vitalhub: Digesting Acquisitions While Preparing For More (TSX:VHI:CA)

NioCorp: A Speculative Buy On The Development Of Domestic U.S. Critical Mineral Supply

SPX Technologies, Inc. (SPXC) Presents at Baird 2026 Global Industrial Conference 2026 Transcript

Northland Power: From Construction Cycle To Cash Flow Compounder (NPI:CA)

Voya GNMA Income Fund Q3 2026 Commentary

Editors Picks

Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript

16 November 2026

TOYO Co., Ltd. (TOYO) Q3 2026 Earnings Call Transcript

16 November 2026

Creative Realities, Inc. (CREX) Q3 2026 Earnings Call Transcript

16 November 2026

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

16 November 2026

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts

Vitalhub: Digesting Acquisitions While Preparing For More (TSX:VHI:CA)

16 November 2026

NioCorp: A Speculative Buy On The Development Of Domestic U.S. Critical Mineral Supply

16 November 2026

SPX Technologies, Inc. (SPXC) Presents at Baird 2026 Global Industrial Conference 2026 Transcript

16 November 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.